Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib
- PMID: 21099346
- DOI: 10.4161/cbt.11.3.14099
Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib
Abstract
Two separate clinical studies of advanced hepatocarcinoma patients recently reported that the multikinase inhibitor sorafenib (nexavar) could extend survival of the patients only by 2-3 months. We also previously demonstrated that 4'-(p-toluenesulfonylamido)-4-hydroxychalcone (TSAHC) blocks the multilayer growth and migration mediated by TM4SF5, which is highly expressed in approximately 80% of Korean hepatocarcinoma patients. Therefore, we wondered how TSAHC might be different from sorafenib to deal with hepatocarcinoma in terms of the therapeutic characteristics including specificity for TM4SF5. TM4SF5 is previously shown to mediate tumorigenesis through cytosolic p27Kip1-mediated inactivation of RhoA, epithelial-mesenchymal transition, multilayer growth, migration, invasion, and tumor angiogenesis. In this study, TSAHC and two derivatives showed similar antagonistic activities against TM4SF5-mediated signaling and multilayer growth in vitro and anti-tumorigenic activity even in early stages of TM4SF5-mediated tumor formation in nude mice. Meanwhile, sorafenib was only effective much later in tumorigenesis in vivo and affected in vitro proliferation in a TM4SF5-independent manner. Altogether, these observations suggest that TSAHC may be a promising anti-tumorigenic reagent, especially against TM4SF5-mediated hepatocarcinoma.
Similar articles
-
Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative.Hepatology. 2009 Apr;49(4):1316-25. doi: 10.1002/hep.22777. Hepatology. 2009. PMID: 19177595
-
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12. Int J Cancer. 2012. PMID: 21858812
-
Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis.J Cell Biochem. 2010 Sep 1;111(1):59-66. doi: 10.1002/jcb.22662. J Cell Biochem. 2010. PMID: 20506553
-
Modulation of signaling between TM4SF5 and integrins in tumor microenvironment.Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1752-8. doi: 10.2741/3818. Front Biosci (Landmark Ed). 2011. PMID: 21196261 Review.
-
Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.Curr Med Chem. 2012;19(7):938-44. doi: 10.2174/092986712799320736. Curr Med Chem. 2012. PMID: 22214462 Review.
Cited by
-
Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity.Theranostics. 2017 Jan 11;7(3):594-613. doi: 10.7150/thno.15629. eCollection 2017. Theranostics. 2017. PMID: 28255353 Free PMC article.
-
Antiangiogenic Effect of Flavonoids and Chalcones: An Update.Int J Mol Sci. 2017 Dec 22;19(1):27. doi: 10.3390/ijms19010027. Int J Mol Sci. 2017. PMID: 29271940 Free PMC article. Review.
-
TM4SF5-mediated liver malignancy involves NK cell exhaustion-like phenotypes.Cell Mol Life Sci. 2021 Dec 18;79(1):49. doi: 10.1007/s00018-021-04051-x. Cell Mol Life Sci. 2021. PMID: 34921636 Free PMC article.
-
Differential regulation of cellular functions by the C-termini of transmembrane 4 L six family proteins in 2- or 3-dimensional environment.Oncotarget. 2017 Feb 21;8(8):13277-13292. doi: 10.18632/oncotarget.14809. Oncotarget. 2017. PMID: 28129652 Free PMC article.
-
Flavonoids with Anti-Angiogenesis Function in Cancer.Molecules. 2024 Mar 31;29(7):1570. doi: 10.3390/molecules29071570. Molecules. 2024. PMID: 38611849 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical